Dole Announces its Promises, Bringing Interdependent Prosperity to People and the Planet
30.6.2020 10:00:00 EEST | Business Wire | Press release
Dole Packaged Foods and Dole Asia Fresh, divisions of Dole Asia Holdings Pte. Ltd.. announced today “The Dole Promise,” which aims to increase access to sustainable nutrition, decrease food waste, plastics in packaging and carbon emissions and grow value for the company’s stakeholders, including farmers and shareholders.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200630005347/en/
The Dole Promise, inspired by Japanese philosophy, Sampo Yoshi. (Graphic: Business Wire)
“The Dole Promise reflects the recognition that 'business as usual' is unacceptable in the face of a looming food crisis and the growing expectations of the next generation," said Pier Luigi Sigismondi, President of Dole Packaged Foods. “The impacts of the COVID-19 global pandemic could see 265 million additional people pushed to the brink of starvation by the end of this year,1 double the numbers of last year. At the same time, the challenges of climate change, resource waste and declining natural resources still must be addressed. We believe it is time for a change, and we are taking action where we can be most effective – within our own business.”
The promise draws on the spirit of ‘Sampo Yoshi,’ an 18th century Japanese philosophy that views the well-being of society and business as interdependent, and ensures the business is beneficial to the seller, to the buyer and to the community.
“The triple-win concept of ‘Sampo Yoshi’ has been part of Japanese culture for centuries, and is now at the heart of The Dole Promise as we play our part in helping to restore balance in the world by doubling down on our mission to put the health of the planet at the heart of everything we do,” said Richard Toman, President Dole Asia Fresh Division. “It’s a promise that Dole is making to do business differently, and to join forces with those who are equally committed to bringing back the goodness of the earth.”
The Dole Promise frames this philosophy to include:
Better for People:
- Access to sustainable nutrition for 1 billion people by 2025
- Moving towards zero processed sugar in all Dole products by 2025
Better for Planet:
- Moving towards zero fruit loss from Dole farms to markets by 2025
- Moving towards zero fossil-based plastic packaging by 2025
- Aiming for net zero carbon emissions in Dole operations by 2030
Better for all Stakeholders:
- Dole will continue to positively impact all farmers, communities and people working for Dole – through its commitment to equal opportunity, living wages, and an ever-increasing level of safety, nutrition, and wellbeing. The company also seeks to advance human rights within the direct operations and supply chains by building a culture of transparency and accountability. The company also aims for a 50% increase in the value of its business by 2025.
The growing problem of food inequality, which existed before the pandemic, has now reached crisis proportions and needs a collective effort to address. Dole’s commitment to increase access to sustainable nutrition will play a role, along with its effort to eliminate food waste.
“Our promise is not just about improving our world today,” said Sigismondi. "We have a responsibility to future generations to work towards a more equitable and sustainable future.”
The launch video, “Dear Leaders of the World,” gives voice to the concern of today’s youth about their generation’s future if something doesn’t change now.
“The next generation is right to question why we have left problems like climate change for so long. There are inter-generational repercussions. That is why we are increasing our efforts in key areas like reducing carbon emissions and working towards removing plastic packaging from our supply chain. Our promise puts the heart of the planet and people at the center of everything we do,” added Sigismondi.
Elevating the end-to-end value chain
Addressing the many gaps in access to good nutrition and reduction of waste cannot be done alone. Dole is partnering with Solidaridad; an international civil society organization with over fifty years of experience in creating fair and sustainable supply chains from producer to consumer across five continents. They are developing innovative solutions for healthy and sustainable food systems ensuring that farmers and workers have a living income, influence over their destiny, and can produce in balance with nature. Dole is also enlisting the help of Forum for the Future, an organisation that works in partnership with business, governments and civil society to accelerate the shift toward a sustainable future, Future Food Institute a center of excellence for food intelligence and the food innovation ecosystem and Rocana, a venture capital firm focused on clean and functional nutrition.
Later this year, Dole is launching the Sunshine for All™ Investment Fund to support additional strategic partnerships and strategic investments in these areas around the world. The US$2 million annual fund will work with innovators, start-ups and progressive partners to help deliver on the Dole Promise in key areas such as nutrition products, materiality, advisory and implementation of crucial practices to help achieve the ambitions that have been set.
Additionally, Dole is bringing these commitments inside their company walls, with employee programs that educate and encourage all Dole employees to live “The Dole Promise.”
To see the full details of the Dole Promise and the Sunshine for All investment fund visit sunshineforall.com and download the Dole Promise visual here .
Dole Asia Holdings Pte. Ltd.
Dole Asia Holdings Pte. Ltd., is a worldwide leader and innovator in the production and marketing of high-quality packaged fruit and healthy snacks. Dole Asia Holdings is also one of Asia's largest producers and marketers of high-quality fresh fruits and vegetables. For more information please visit dolesunshine.com or doleintlcsr.com. The Dole Promises are from the Dole Asia Holdings group of companies, and apply to their products, which can be seen at sunshineforall.com
1 https://www.mercycorps.org/blog/quick-facts-global-hunger#global-hunger
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200630005347/en/
Contact information
MEDIA CONTACT:
Brittney Theriault
btheriault@golin.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
